280 239

Cited 0 times in

갑상선 암의 분자 진단

DC FieldValueLanguage
dc.contributor.author이슬기-
dc.contributor.author이잔디-
dc.contributor.author조영석-
dc.date.accessioned2016-02-04T11:48:01Z-
dc.date.available2016-02-04T11:48:01Z-
dc.date.issued2015-
dc.identifier.issn1598-1703-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/141230-
dc.description.abstractWith increasing prevalence of thyroid nodules, clinicians are increasingly impelled to identify the optimal predictor of thyroid cancer, with the goal of guiding management based on assessed risk. Fine-needle aspiration cytology is the gold standard diagnostic method for thyroid nodules. However, fine-needle aspiration cytology is not perfect and adjuncts which might complement its predictive value are being investigated from several innovative perspectives. For these vigorous efforts, remarkable advances have been achieved in understanding several major biologic areas of thyroid cancer, including the molecular alterations for loss of radioiodine avidity of thyroid cancer, the pathogenic role of the MAP kinase and PI3K/Akt pathways and their related genetic alterations in thyroid tumorigenesis and pathogenesis. These exciting advances provide unprecedented opportunities for development of molecular-based novel diagnostic and therapeutic strategies for thyroid cancer. The common somatic genetic changes in thyroid cancer of follicular cell origin (RET/PTC, NTRK, RAS, BRAF, PAX8-PPARγ) are generally mutually exclusive, with distinct genotype–histologic subtype associations of thyroid cancer. Mutation analysis in fine needle aspiration samples has been applied to improve the diagnostic accuracy. In studies regarding gene expression profiling, aberrant gene methylation and miRNA have shown significant progress toward identification of biomarkers that could improve the accuracy of fine needle aspiration cytology in the evaluation of patients with thyroid nodule and prediction of disease aggressiveness. Future clinical trials evaluating the accuracy and cost-effectiveness of applying these biomarkers in the management of thyroid neoplasm should be considered.-
dc.description.statementOfResponsibilityopen-
dc.format.extent53~59-
dc.relation.isPartOfKorean journal of Endocrine Surgery (대한내분비외과학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title갑상선 암의 분자 진단-
dc.title.alternativeMolecular Testing in Diagnosis of Thyroid Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentYonsei Biomedical Research Center (연세의생명연구원)-
dc.contributor.googleauthor이슬기-
dc.contributor.googleauthor조영석-
dc.contributor.googleauthor이잔디-
dc.identifier.doi10.16956/kaes.2015.15.3.53-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03066-
dc.contributor.localIdA03853-
dc.contributor.localIdA02909-
dc.relation.journalcodeJ02002-
dc.subject.keywordThyroid neoplasms-
dc.subject.keywordMolecular testing-
dc.subject.keywordMutation-
dc.subject.keywordMicroRNAs-
dc.contributor.alternativeNameLee, Seul Gi-
dc.contributor.alternativeNameLee, Jan Dee-
dc.contributor.alternativeNameJo, Young Suk-
dc.contributor.affiliatedAuthorLee, Jan Dee-
dc.contributor.affiliatedAuthorJo, Young Suk-
dc.contributor.affiliatedAuthorLee, Seul Gi-
dc.rights.accessRightsfree-
dc.citation.volume15-
dc.citation.number3-
dc.citation.startPage53-
dc.citation.endPage59-
dc.identifier.bibliographicCitationKorean journal of Endocrine Surgery (대한내분비외과학회지), Vol.15(3) : 53-59, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.